Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
– Risk of death was reduced by 53% in patients treated with enfortumab vedotin plus pembrolizumab compared to chemotherapy –...

Fielding Lapses in Kanpur Show Why Uttar Pradesh Cannot Rely Solely on Batting Power
Ashok Leyland share price jumps 11.65% on 23% rise in October CV sales
Afghanistan beat Zimbabwe in Sharjah: 72-run Test win seals 1-0 series, T20I win by seven wickets
Sensex surges 1,600 points as oil slides after U.S. midterm results lift risk appetite
Doncic scores 40 as Lakers beat Kings 116-103 at Golden 1 Center 



























